Molecular Partners AG
https://www.molecularpartners.com/
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Molecular Partners AG
Will Pfizer's Paxlovid Go The Lagevrio Way In India?
While the Medicines Patent Pool has sub-licensed Paxlovid to multiple Indian firms, it isn’t approved in the country yet. It will get there, but molnupiravir’s sales might give an indication of what is in store for Pfizer’s oral antiviral COVID-19 treatment post a lost opportunity with vaccine Comirnaty.
Tech Transfer Roundup: MD Anderson, Moffitt Lead Busy Academic Cancer Partnering Space
MD Anderson teams with Eisbach on precision oncology and with Yingli on a five-year translational research effort. Moffitt inks tie-ups with Dyve and Turnstone.
Novartis Sticks With Bolt-Ons As Biotech Bubble Bursts
Rather than major M&A, CEO Vas Narasimhan has told Scrip that Novartis will carry on doing development and licensing deals and while the firm has noted that the valuations of prospective biotech deals have fallen, "they still remain relatively high."
J.P. Morgan Day 1: Pharma Execs Offer Big Talk Instead Of Big Deals
Daily notebook from the virtual J.P. Morgan Healthcare Conference: business development is top of mind for BMS, Merck, J&J and Pfizer, while Novartis, Moderna and Regeneron talk about next steps. Bayer looks to minimize Xarelto patent expiry, a new chief exec debuts for Alnylam and EY suggests 2022 will be another year of bolt-on deals.
Company Information
- Industry
- Biotechnology
- Pharmaceuticals
-
Biotechnology
- Large Molecule
-
Drug Discovery Tools
- Genomics-Proteomics